Department of Medicine, University of California San Francisco, San Francisco, CA.
Liver Transpl. 2015 Apr;21(4):423-34. doi: 10.1002/lt.24080.
Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced because of HCV recurrence after transplant. Interferon-based antiviral treatment administered either before or after transplant to prevent or treat HCV recurrence, respectively, is limited because of poor tolerability and low efficacy. However, the treatment of HCV in the transplant setting is changing considerably with the availability of newer direct-acting antivirals and interferon-free regimens. This article will review the experience to date with treating HCV in the setting of cirrhosis and liver transplantation and will discuss the unique challenges encountered when this population is being treated.
尽管慢性丙型肝炎病毒 (HCV) 感染是美国肝移植的主要适应证，但由于移植后 HCV 复发，移植物和患者的存活率降低。在移植前后分别使用干扰素为基础的抗病毒治疗来预防或治疗 HCV 复发，但由于耐受性差和疗效低而受到限制。然而，随着新型直接作用抗病毒药物和无干扰素方案的出现，肝移植患者 HCV 的治疗正在发生重大变化。本文将回顾目前在肝硬化和肝移植背景下治疗 HCV 的经验，并讨论治疗该人群时遇到的独特挑战。
